TRANSLATE BIO
Translate Bio is a biotechnology company that in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
TRANSLATE BIO
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2011-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.translate.bio
Total Employee:
101+
Status:
Closed
Contact:
(617) 945-7361
Email Addresses:
[email protected]
Total Funding:
442.63 M USD
Technology used in webpage:
SPF Amazon ASP.NET IIS IIS 10 Amazon Ohio Region NameBright Tierpoint
Similar Organizations
10X Genomics
10X Genomics ELV solutions and security systems company that provides an innovative genomics platform.
23andMe
23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Immunome
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery.
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Micropep Technologies
Micropep Technologies is a biotech company that focused on biological alternatives to agrochemicals.
Vaxart
Vaxart is a biotechnology company that develops vaccine technology for the treatment of infectious diseases.
Zymeworks
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Omega Funds
Omega Funds investment in Series C - Translate Bio
The Baupost Group
The Baupost Group investment in Series C - Translate Bio
Fidelity
Fidelity investment in Series C - Translate Bio
The Baupost Group
The Baupost Group investment in Series C - Translate Bio
Fidelity
Fidelity investment in Series C - Translate Bio
Atlas Venture
Atlas Venture investment in Series C - Translate Bio
SR One
SR One investment in Series C - Translate Bio
MRL Ventures Fund
MRL Ventures Fund investment in Series C - Translate Bio
Omega Funds
Omega Funds investment in Series C - Translate Bio
Monsanto Growth Ventures (MGV)
Monsanto Growth Ventures (MGV) investment in Series B - Translate Bio
Official Site Inspections
http://www.translate.bio
- Host name: ec2-54-247-151-159.eu-west-1.compute.amazonaws.com
- IP address: 54.247.151.159
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Translate Bio"
Sanofi to Buy Translate Bio, Expanding mRNA Tech | Sanofi
Aug 3, 2005 · Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene …See details»
Sanofi completes acquisition of Translate Bio, accelerating the ...
PARIS– September14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines …See details»
Translate Bio - Crunchbase Company Profile & Funding
Translate Bio is a biotechnology company that in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company developing a new class of potentially …See details»
Sanofi and Translate Bio expand collaboration to develop mRNA …
Jun 23, 2004 · Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene …See details»
Sanofi concludes acquisition of Translate Bio for $3.2bn
Sep 15, 2021 · With the acquisition, Translate Bio will continue as a surviving corporation and work as an indirect, fully owned unit of Sanofi. Sanofi and Translate Bio signed a partnership and exclusive licence agreement in June …See details»
Translate Bio - AnnualReports.com
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Their proprietary mRNA therapeutic platform (MRTTM) is …See details»
Sanofi completes acquisition of Translate Bio, accelerating the ...
PARIS – September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines …See details»
Translate Bio Buyout Shows Growing Hunger for mRNA …
Aug 17, 2021 · Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA …See details»
Translate Bio Announces Agreement with Sanofi …
Jun 11, 2018 · Translate Bio announced a multi-year research and development collaboration with Sanofi Pasteur to develop mRNA vaccines for infectious diseases.See details»
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA …
Aug 3, 2021 · PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop …See details»
Sanofi completes acquisition of Translate Bio, accelerating
PARIS – September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines …See details»
Sanofi to buy partner Translate Bio for $3.2bn in mRNA push
Aug 3, 2021 · French pharmaceutical group Sanofi will acquire its partner Translate Bio for $3.2bn, as it makes a big bet on the future of messenger RNA as a transformative technology …See details»
Sanofi completes acquisition of Translate Bio, accelerating the ...
PARIS – September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines …See details»
Translate Bio - Funding, Financials, Valuation & Investors
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.See details»
Sanofi to Acquire Translate Bio; Advances Deployment of
Mar 8, 2021 · Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene …See details»
Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2
Aug 3, 2021 · next-generation mRNA technology after setbacks in the COVID-19 vaccine race, confirming a Reuters exclusive report. Sanofi said it would acquire all outstanding shares of …See details»
Translate Bio Announces Key Leadership Additions and
Apr 19, 2021 · Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene …See details»
Translate Bio Announces Second Quarter 2021 Financial Results …
LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of …See details»
Translate Bio: New Management, Aggressive mRNA Pipeline, And ...
Apr 23, 2021 · Translate Bio has reemerged in 2021 with new management, +$650M in funding and Sanofi partnership that will aid their pipeline of mRNA therapeutics and vaccines.See details»
Translate Bio Announces Key Leadership Additions and Promotions
LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of …See details»